Alzheimer’s Drugs Are Finally Tackling the Disease Itself. Here’s How

While our understanding of Alzheimer’s disease is far from complete, the latest therapies, and others in more than 100 clinical trials, offer new hope ... Read More

Controversial New Alzheimer’s Treatments Gain Ground despite Serious Side Effects

One of neurologist Anelyssa D’Abreu’s least favorite tasks is giving her patients a dreaded diagnosis: early-stage Alzheimer’s disease. Unlike a decade ago, when D’Abreu had little to offer her ... Read More

Controversial New Alzheimer’s Drugs Offer Hope—But at a High Cost

New Alzheimer’s drugs known as anti-amyloid therapies may slow disease progression—but they also carry serious risks, including brain bleeds and strokelike symptoms ... Read More

Experimental Med Tied to Slowed Alzheimer’s Biomarker Progression

TORONTO — The experimental drug obicetrapib, a potent oral cholesteryl ester transfer protein (CETP) inhibitor, significantly slowed Alzheimer’s disease (AD) biomarker progression over 12 months in ... Read More

‘As close as one could get to living a near-normal life’: Experimental narcolepsy drugs bring hope to patients

Several drug makers are racing to win approval of a new class of drugs that could transform how the rare sleep disorder is treated. Read More

Using new blood biomarkers, researchers find Alzheimer's disease trial eligibility differs among various populations

Some of the populations with the highest risk for Alzheimer's disease remain greatly underrepresented in clinical trials—and a new study helps explain why. Read More